LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Ever Saliva-Based Concussion Test to Be Available in 2023

By LabMedica International staff writers
Posted on 21 Nov 2022
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)

According to the (CDC), 1.6 to 3.8 million athletes will experience a sports-related mild traumatic brain injury (mTBI) or concussion each year. Despite increased public awareness, clinical guidelines still rely on subjective symptom scales to diagnose and manage concussions. Furthermore, there are currently no biological tests to diagnose mTBI. Now, new research has revealed that biomarkers found in saliva may distinguish mTBI and parallel symptom recovery.

By analyzing brain derived biomarkers found in saliva, scientists at Quadrant Biosciences (Syracuse, NY, USA), in collaboration with Penn State (Hershey, PA, USA) and the State University of New York (New York, NY, USA), have developed a novel diagnostic test for concussion. These biomarkers can confirm mTBI when run through Quadrant’s proprietary artificial intelligence platform. The Clarifi mTBI Saliva Test being developed by Quadrant uses small non-coding RNAs found in the saliva to help diagnose concussions. The U.S. Patent and Trademark Office (USPTO) has awarded the company and its academic partners with a patent for the analysis and prediction of mTBI and concussion symptoms. Quadrant has started discussions about potentially licensing this technology to third-parties, and the test is expected to be available in late 2023.

"Our motivation for developing this technology was to prevent further harm to the kids, athletes, and adults who experience mild, moderate, or repetitive head impacts," said Dr. Frank Middleton, PhD, Professor at SUNY Upstate Medical University, who led the patented research. "While most of the field has focused on peripheral blood measures, for the past decade we worked extensively to establish the utility of quantifying small RNA molecules in saliva as predictors of concussion or long-lasting symptoms from head impacts."

"As a pediatrician who provides medical care for children and teens with concussion, I am excited by the potential of this technology to improve the way clinicians manage this common injury. A saliva-based test for concussion could provide a novel addition to the physician toolbox," said Dr. Steve Hicks, MD, PhD, at Penn State College of Medicine, who was also among the ones to lead the patented research.

Related Links:
Penn State
Quadrant Biosciences
State University of New York 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more